SLC25A20

Mitochondrial carnitine/acylcarnitine carrier protein · O43772 · SLC25A20 on Sugi Atlas →

3,530 patent compounds predicted against SLC25A20, 2,557 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Palmitoyl-Carnitine (SCHEMBL115183)	1.00	3/20
Palmitoyl-Carnitine (SCHEMBL116634)	1.00	3/20
Palmitoyl-Carnitine (SCHEMBL187668)	1.00	3/20
SCHEMBL187973	1.00	3/20
SCHEMBL188358	1.00	3/20
SCHEMBL188359	1.00	3/20
SCHEMBL188470	1.00	3/20
SCHEMBL198686	1.00	3/20
SCHEMBL234694	1.00	3/20
Octanoylcarnitine (SCHEMBL236560)	1.00	3/20
SCHEMBL288242	1.00	3/20
SCHEMBL288673	1.00	3/20
Palmitoyl-Carnitine (SCHEMBL855471)	1.00	3/20
SCHEMBL1958560	1.00	3/20
Octanoylcarnitine (SCHEMBL2915508)	1.00	3/20
SCHEMBL2936666	1.00	3/20
Octanoylcarnitine (SCHEMBL3448414)	1.00	3/20
SCHEMBL235082	0.97	3/20
Hydrochloric Acid (SCHEMBL307401)	0.97	3/20
Palmitoyl-Carnitine (SCHEMBL527281)	0.97	3/20

Clinical trials — most relevant to SLC25A20 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Evaluation of the Effects of L-Carnitine Injection in Patients Undergoing Hemodialysis	PHASE4	UNKNOWN
Identification of Carnitine-Responsive Cardiomyopathy	PHASE4	UNKNOWN
Effects of L-Carnitine in Amyotrophic Lateral Sclerosis Patients With CHCHD10 Mutations	PHASE4	COMPLETED
Phase III Trial of Coenzyme Q10 in Mitochondrial Disease	PHASE3	COMPLETED
Effects of Coenzyme Q10 on Charcot-Marie-Tooth Disease	PHASE1/PHASE2	COMPLETED
Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects	PHASE2	COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
Acetylcarnitine and Insulin Sensitivity	PHASE2	COMPLETED
Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients	PHASE2	COMPLETED
The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC	PHASE1/PHASE2	UNKNOWN
Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension	PHASE1	COMPLETED
Does Clinical Treatment of Mitochondrial Dysfunction Impact Autism Spectrum Disorder (ASD)?	PHASE1	UNKNOWN
Expression of SLC25A48 in Chronic Obstructive Pulmonary Disease	nan	NOT_YET_RECRUITING
Effects of Parenteral L-carnitine Supplementation in Premature Neonates	nan	COMPLETED
Independent and Additive Effects Of Micronutrients With Metformin In Patients With PCOS	nan	COMPLETED
Multi-omics Study in Citrin Deficiency	nan	ACTIVE_NOT_RECRUITING
Acylcarnitine Profile After Intensive Care	nan	UNKNOWN
Nutritional Therapy of the Deficits of Oxidation Mitochondrial of the Fatty Acids	nan	COMPLETED
Nephroprotective Effects of Carnitine and (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN)	nan	UNKNOWN
Systemic Biomarkers of Brain Injury From Hyperammonemia	nan	RECRUITING
Survey on Supplement Use in Mitochondrial Disease	nan	COMPLETED
The Analysis of Fatigue on Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia	nan	UNKNOWN
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy	nan	COMPLETED
Tissue Sample Study for Mitochondrial Disorders	nan	ENROLLING_BY_INVITATION
Influence of OCTN2 Variants on Carnitine Status and Plasma Triglycerides	nan	COMPLETED
The Natural History of Mitochondrial Diseases	nan	RECRUITING
North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)	nan	RECRUITING
Gastrointestinal Dysfunction in Children Affected With Mitochondrial Disorders	nan	COMPLETED
Longitudinal Study of Mitochondrial Hepatopathies	nan	SUSPENDED
A Prospective Study of the Disease Characteristics of Adult Patients With Long Chain Fatty Acid Oxidation Disorders	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC25A20 binder may also engage these)

Protein	Name	Similarity
Q8HXY2	—	1.000	Q8HXY2 →
Q9Z2Z6	—	0.999	Q9Z2Z6 →
P97521	—	0.994	P97521 →
O97649	—	0.948	O97649 →
SLC25A4	ADP/ATP translocase 1	0.944	landscape →
P02722	—	0.943	P02722 →
Q6QRN9	—	0.943	Q6QRN9 →
O77792	—	0.942	O77792 →
Q9N2J1	—	0.941	Q9N2J1 →
P32007	—	0.940	P32007 →
Q9N2I9	—	0.940	Q9N2I9 →
Q5U680	—	0.940	Q5U680 →
Q000K2	—	0.939	Q000K2 →
Q3SZI5	—	0.939	Q3SZI5 →
Q6GLA2	—	0.939	Q6GLA2 →
Q5R5A8	—	0.938	Q5R5A8 →
P70406	—	0.938	P70406 →
P55851	—	0.937	P55851 →
P51881	—	0.937	P51881 →
A6QR09	—	0.937	A6QR09 →
Q5R5A1	—	0.937	Q5R5A1 →
Q9W725	—	0.936	Q9W725 →
Q70HW3	—	0.936	Q70HW3 →
SLC25A6	ADP/ATP translocase 3	0.936	landscape →
P48962	—	0.936	P48962 →
P56500	—	0.935	P56500 →
Q05962	—	0.935	Q05962 →
P56499	—	0.935	P56499 →
P56501	—	0.935	P56501 →
O46373	—	0.935	O46373 →